Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study

BACKGROUND: Remdesivir, an antiviral agent able to reduce inflammatory cascade accompanying severe, life-threatening pneumonia, became the first drug approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus 2 related severe acute respiratory syndrome (...

Descripción completa

Detalles Bibliográficos
Autores principales: Biancalana, Edoardo, Chiriacò, Martina, Sciarrone, Paolo, Mengozzi, Alessandro, Mechelli, Sandra, Taddei, Stefano, Solini, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184369/
https://www.ncbi.nlm.nih.gov/pubmed/34113086
http://dx.doi.org/10.2147/CIA.S313028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184369/
https://www.ncbi.nlm.nih.gov/pubmed/34113086
http://dx.doi.org/10.2147/CIA.S313028

Ejemplares similares